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glomerular filtration rate (eGFR) (mL/min) was calculated by Cockcroft-Gault (CG),
the mean bivalirudin dose achieving a therapeutic aPTT (50-80 seconds) was 0.07 ±
0.04, 0.15 ± 0.08, and 0.16 ± 0.07 for patients with an eGFR between 15-30, 31-60,
and >60, respectively (P=NS for 31-60 vs. >60; P<0.001 for 15-30 vs. 31-60). When
eGFR (mL/min/1.73 m2) was calculated by the Modification of Diet in Renal Disease
(MDRD) formula, the mean dose acheiving a therapeutic aPTT was 0.07 ± 0.04, 0.12
± 0.07, and 0.20 ± 0.07 for patients with eGFR between 15-30, 31-60, >60, respectively
(P<0.001 for 31-60 vs. >60 and 15-30 vs. 31-60; figure). No differences in adverse
clinical outcomes were observed.
Conclusion: Patients with suspected HIT receiving prolonged bivalirudin in the setting
of renal dysfunction can be treated safely and effectively following dose adjustments
in those with MDRD-determined moderate and severe renal impairment.
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Background: Bleeding complicating acute coronary syndrome (ACS) invasive care
is associated with increased ischemic events and mortality. Current anticoagulants are
limited by unpredictable pharmacodynamics and lack of specific reversibility. We
evaluated the effects of the REG1 System, an RNA aptamer, direct factor IXa inhibitor,
pegnivacogin, and its active control agent, animaversen, on access and non-access site
bleeding.
Methods: RADAR was a phase 2 trial evaluating the safety and efficacy of
anticoagulation with REG1 in non-ST-elevation ACS and planned early catheterization
via femoral access. A total of 640 patients were randomized 2:1:1:2:2 to pegnivacogin
with 25%, 50%, 75%, or 100% reversal with anivamersen with sheath removal at 10
minutes, or to heparin with sheath removal per standard care. Access and non-access
site bleeding at 30 days was assessed (ACUITY scale).
Results: Overall bleeding rates were similar across groups, with a trend toward less
major bleeding with more complete pegnivacogin reversal. Bleeding severity and
locations are shown (Table). The 25% reversal arm was terminated early due to excess
bleeding. One patient in the heparin arm had an intracranial bleed. Most bleeding
occurred ≤48 hours of randomization (81.1% with REG1 vs. 80% with heparin).
Conclusion: In non-ST ACS patients undergoing early invasive management, major
bleeding occurs in 10% of cases and is most often related to the vascular access site.
The REG1 System, with ≥ 50% reversal and early sheath removal resulted in similar
rates and severity of bleeding compared with heparin and standard sheath removal.
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Background: The EUROVISION Registry was designed to capture patterns of use
and short term outcomes associated with the use of bivalirudin (BIV) during PCI
procedures in Europe.
Methods: A total of 2018 consecutive BIV-treated patients (75% male, mean age 65.5
years) were included from 58 sites in 5 countries (Germany, Italy, France, Austria,
United Kingdom). In-hospital and 30-day outcomes were collected and included:
Death, MI, stroke, revascularization, major and minor bleeding, stent thrombosis and
thrombocytopenia.
Results: Indication for PCI included STEMI (34%), NSTEMI (25%), unstable angina
(16%) and stable angina (26%) with a median procedural duration of 28 minutes.
Overall, P2Y12 inhibitor preloading occurred in 95% of patients (91% clopidogrel
{65% with 600 mg and 33% with 300mg}, 9% prasugrel), 45% of patients received
other antithrombin therapy prior to PCI and were then switched to BIV, while
procedural glycoprotein inhibitor (GPI) use was low at 4.2%. Activated clotting time
was checked in only 2.8% suggesting operator familiarity with BIV predictable mode
of action and treatment effect. Among STEMI patients, 62% received a post-procedural
BIV infusion for a median duration of 122 minutes. Safety measures included major
bleeding (1.6%), stroke (5/2018, 0.2%), thrombocytopenia (0/2018), and stent
thrombosis (6/2018, 0.3%). Overall mortality was 1.0%, myocardiaI infarction rate
was 1.1% and urgent revascularization was 0.8%.
Conclusion: Adaptation of BIV as the foundation for all-comer PCI (including high
percentage of STEMI and NSTEMI patients) is associated with excellent ischemic
protection and unsurpassed safety. The rates observed in EUROVISION compare
favorably to other large existing registry datasets.
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Background: REG1 consists of pegnivacogin, an RNA aptamer factor IX inhibitor,
and its active controlling agent, anivamersen. RADAR assessed the safety and efficacy
of REG1 in patients with acute coronary syndromes (ACS) undergoing catheterization
via femoral access. REG1’s safety and efficacy in patients undergoing PCI has not
been described.
Methods: Patients were randomized in a 2:1:1:2:2 fashion to REG1 with 25%, 50%,
75% or 100% reversal, or heparin. The primary safety and efficacy endpoints were a
composite of major and minor ACUITY bleeding and the composite of death,
myocardial infarction, urgent target vessel revascularization (TVR), or recurrent
ischemia through 30 days.
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Results: Of 634 patients, 387 (61%) underwent PCI. The rates of overall and major
bleeding were 68% and 18% (25% reversal), 39% and 12% (50% reversal), 35% and
9% (75% reversal), and 34% and 7% (100% reversal) compared with 38% and 11%
(heparin). Ischemic events were numerically less frequent in REG1 patients vs. heparin
(4.4% versus 7.3%, p=0.3). Urgent TVR was rare (1%) in both REG1 and heparin
groups.
Conclusion: High level factor IX inhibition coupled with at least 50% reversal of
pegnivacogin activity may represent an attractive strategy in ACS patients undergoing
PCI and deserves testing in adequately powered phase 3 clinical trials.
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Background: Bivalirudin (BIV) has been shown to reduce bleeding complications
compared to unfractionated heparin (UFH) after coronary intervention. The
“Preclosure” technique with a suture-based closure device (VCD) has been reported
to achieve hemostasis after procedures with large caliber arterial sheaths. Clinical
outcomes with BIV, UFH and VCD in balloon aortic valvuloplasty (BAV) have not
been reported.
Methods: In this BAV registry report, we analyzed 354 patients who underwent 432
consecutive procedures (2005-2010) in a single referral center. Univariate and
multivariate logistic regression models were used to evaluate associations between
baseline characteristics, BIV vs. UFH use, VCD vs. manual compression use, and in-
hospital outcomes.
Results: The study cohort is divided in to four groups as shown in the figure. There
were a total of 47 (10.9%) bleeding complications in-hospital: 29 (6.7%) were major
and 18 (4.2%) were minor. The figure shows these results in the 4 groups. There were
no significant differences in the incidence of other vascular complications (group 1:
7.7%, group 2: 3.7%, group 3: 5.3% and group 4: 4.7%; p=0.91) among the four
groups. Among patients who received VCD, those who received UFH (group 2) had
higher mortality compared to those who received BIV (group 4) (8.9% vs. 3.8%,
HR=3.5, 95% CI: 1.2 to 10.2; p=0.025); Among patients treated with BIV, those who
did not receive VCD (group 3) had higher mortality compared to those who received
VCD (group 4) (14.9% vs. 3.8%, HR=4.8, 95% CI: 1.8-12.7; p=0.001).
In-hospital bleeding complications among the four groups.
Conclusion: The combined use of bivalirudin and the “preclosure” technique using
the suture-based VCD was associated with very low bleeding complications after BAV,
and a favorable mortality trend. Fully adjudicated data according to V-ARC and B-
ARC definitions will be presented.
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Background: High on-treatment platelet reactivity (HOPR) in patients on clopidogrel
is associated with adverse events following PCI. The impact of presentation with acute
coronary syndrome (ACS) upon platelet reactivity, however, is not well-understood.
Methods: Patients received 600 mg clopidogrel and 325 mg aspirin at the time of PCI
and underwent platelet reactivity testing with Vasodilator Stimulated Phosphoprotein
Phosphorylation (VASP) 6-24 hours after PCI. HOPR was defined as VASP platelet
reactivity index >50%. ACS was defined as ≥2 of the following: 1) symptoms
consistent with myocardial ischemia; 2) ST elevation or depression ≥1 mm in ≥2
contiguous leads on EKG; 3) cardiac troponin level above upper limit of normal. VASP
platelet reactivity index and HOPR were compared between groups using the Wilcoxon
and Chi-square tests, respectively. Multivariable logistic regression was used to assess
the independent effect of ACS upon HOPR.
Results: 377 patients were enrolled, of whom 12.9% presented with ACS. Patients
with ACS were less likely to have a history of CAD (22.4% v. 59.8%) or previous PCI
(12.5 v. 46.6%) and more likely to have a history of congestive heart failure (22.4%
vs. 11.6%) or a left anterior descending lesion (47.8% v. 30.2%; p <0.001 for all
comparisons). Median VASP platelet reactivity index was higher in ACS patients
(52.6% v. 38.3%, p=0.02), as was incidence of HOPR (55.1% v. 34.6%, p=0.007).
Following multivariable adjustment, ACS remained significantly associated with
HOPR (OR 2.18, 95% CI 1.15-4.12, p=0.02; Table).
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